We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current APLS market cap is 5.7B. The company's latest EPS is USD -4.3591 and P/E is -10.81.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 22.06M | 22.66M | 44.85M | 94.97M | 110.4M |
| Operating Income | -152.94M | -164.05M | -175.08M | -120.44M | -137.08M |
| Net Income | -191.27M | -165.99M | -177.78M | -122.04M | -140.24M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 250.65M | 66.56M | 75.42M | 396.59M |
| Operating Income | -288.02M | -213.73M | -536.28M | -594.61M | -517.12M |
| Net Income | -304.71M | -344.87M | -746.35M | -652.17M | -525.63M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 872.89M | 760.22M | 978.87M | 915.58M | 818.22M |
| Total Liabilities | 565.48M | 590.35M | 566.75M | 570.18M | 585.95M |
| Total Equity | 307.42M | 169.87M | 412.12M | 345.4M | 232.27M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 389.25M | 960.57M | 881.77M | 760.22M | 788.73M |
| Total Liabilities | 355.02M | 756.01M | 683.1M | 590.35M | 594.21M |
| Total Equity | 34.23M | 204.56M | 198.66M | 169.87M | 194.52M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -373M | -513.75M | -177.62M | -327.78M | -496.86M |
| Investing | -64.24M | 59.89M | -259k | -631k | -678k |
| Financing | 381.61M | 365.66M | 391.11M | 392.67M | 398.41M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -211.14M | -160.49M | -563.13M | -513.75M | -594.74M |
| Investing | -1.69M | -316.99M | 247.62M | 59.89M | -674k |
| Financing | 388.54M | 692.18M | 392.24M | 365.66M | 394.5M |
| Market Cap | 5.7B |
| Price to Earnings Ratio | -10.81 |
| Price to Sales Ratio | 14.33 |
| Price to Cash Ratio | 16.19 |
| Price to Book Ratio | 29.22 |
| Dividend Yield | - |
| Shares Outstanding | 120.58M |
| Average Volume (1 week) | 1.65M |
| Average Volume (1 Month) | 1.14M |
| 52 Week Change | -42.86% |
| 52 Week High | 94.75 |
| 52 Week Low | 19.8301 |
| Spread (Intraday) | 0.11 (0.23%) |
| Company Name | Apellis Pharmaceuticals Inc |
| Address |
108 lakeland ave dover, delaware 19901 |
| Website | https://www.apellis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
